本實驗之目的在觀察環胞靈(Cyclosporin, CSA)對矯正橡皮圈引導大白鼠牙齒位移之影響。實驗中共選取64隻5週大Spraque-Dawley大白鼠，隨機分實驗及對照二組(每組各32隻)，實驗組動物又下分高、低劑量兩類(30, 10mg/kg；各16隻)。實驗前後分二階段：先有"環胞靈誘導齒槽骨病變之前置處理期"：實驗組動物先以胃管分別餵食定量之環胞靈或橄欖油(對照組)共二週；再有" 矯正橡皮筋誘導之牙齒位移期"：於經前置處理後之各組動物上顎左側門齒置放矯正用橡皮圈以誘導門齒位移。並分別於置矯正橡皮圈前、後不同時段(前、後、第15分鐘、30分鐘、1小時、2小時、4小時、1天)直接摘取動物門齒硬石膏模型，以測量牙齒位移之變化；再於實驗之第一、三天，犧牲動物製做組織病理切片，以觀察並分析齒朝槽骨受環胞靈藥劑對橡皮圈誘導之影響。結果發現環胞靈對矯正橡皮圈引發牙齒位移有增加之現象(分別發生於橡皮圈置放完成時、後15、30及60分鐘)。在組織病理切片下，在之破骨細胞顯著增加，而在之類骨質顯著增加。而環胞靈藥物對齒槽骨施力及張力側之變化有修飾之現象：實驗組骨骼的整體面積減少、張力側之類骨則較對照組顯著增加。本實驗發現動物牙齒之位移(矯正推力)會因服用CSA而增加，因此證實實驗假說：CSA誘導牙齒位移之臨床現象，不僅是因為牙齦腫大提供了推動之力量；也可能是因為CSA藥物誘導其他之組織(如齒槽骨)病變，促進牙齒位移。
關鍵詞: 牙齒位移，環胞靈，組織病理切片，齒槽骨

英文摘要
The purpose of the present study were to understand the possible mechanisms in the cyclosporin (CSA)-induced tooth migration by (1) evaluating the effects of CSA on orthodontic induced tooth movement and (2) observing the bony changes around dental alveolar under both effect of the CSA and the orthodontic therapy. Sixty-four 5-week old male Sprague-Dawley rats were separated into test and control groups. Rats in the experimental group daily received CSA, 10mg or 30mg/kg body weight (16 rats for each dosage), in mineral oil by gastric feeding for two weeks for inducing the pathological alterations. However, control rats received mineral oil only. Then, an orthodontic elastic ring was inserted on left maxillary central incisor by using two mosquito hemostats. Inter-dental distance between two incisors was assessed at before, immediately after, 5-, 15-, 30-, 60-minuits, and 1- and 3-days of the experiments from the impressed stone models. Animals were sacrificed at day-1 and day-3 for sequential light microscopy histopathological and histometric observations of the alveolar bone turnover in the region. Results showed that significantly increased tooth movement was noted in CSA treated rats at immediately after, 15, 30 and 60 minutes after the band insertion. By light microscopy, the bony area was decreased, however, the osteoid parameters (area and thickness) were increased after CSA therapy. The findings suggest that CSA can aggravate the orthodontic band induced tooth movement, which might play an important role, other than the gingival overgrowth, in CSA-induced tooth migration.
Key words: tooth movement, dental alveolar bone, cyclosporin

正文目錄
緒言------------------------------------------------------------------------ 1- 5
材料與方法------------------------------------------------------------- 6-18
結果----------------------------------------------------------------------- 19-21
討論----------------------------------------------------------------------- 22-25
結論---------------------------------------------------------------------- 26-27
參考文獻-----------------------------------------------------------------28-34
表目錄
表 1: 環胞靈對矯正用橡皮筋誘導牙齒位移之變化 -------------- 35
表2: 近心端齒間骨在環胞靈誘導及橡皮筋作用於組織病理切片下於Bone area，Interdental distances，Suture width之統計分析結果.--------------------------------------------------------------- 36
表3: 遠心端側邊骨在環胞靈誘導及橡皮筋作用於組織病理切片下於Bone area，Osteoclasts，Bone surface，PDL width，Osteoid area，Osteoid width之統計分析結果---------------------- 37
圖1:實驗流程設計圖說明------------------------------------------------ 38
圖2:橡皮筋上於右側門齒區示意圖-------------------------------------- 39
圖3:大白鼠上顎門齒區側面觀示意圖--------------------------------- 40
圖4:切片計算之可分為二部份。a :近心端齒間骨， b :遠心端側邊 骨。A:實驗組 B:對照組 ; Tri-chrome stain ( 130倍)------- 41
圖5:係圖4a近心端齒間骨放大圖--------------------------------- 42
圖6:係圖4b遠心端側邊骨之放大圖--------------------------------- 43
圖7:類骨質的面積及寬度------------------------------------------------- 44
圖8:環胞靈對橡皮筋誘導牙齒位移之影響圖----------------------- 45
圖9A:環胞靈對遠心端側邊骨類骨質面積(1天)之影響之影響圖-- 46
圖9B:環胞靈對遠心端側邊骨類骨質面積(3天)之影響之影響圖-- 47
圖10A:環胞靈對遠心端側邊骨類骨質寬度(1天)之影響之影響圖- 48
圖10B:環胞靈對遠心端側邊骨類骨質寬度(3天)之影響之影響圖- 49
圖11: 橡皮筋上於大白鼠右側門齒區--------------------------------- 50

參考文獻
1. Borel JF. Cyclsperin: historical perspertives. Kahan BD, Cyclosperine biolegical activity and clinical application. Houston, Jne: Gruner & Stratton. 3-13,1984.
2. Borel J.F. Magnee FC and Stahelin H. Effects of the New Antilymphocytic peptide Cyclosporin A in Animals. Immunology 32:1017, 1977.
3. Calne RY. Rolles K, Thiru S, McMaster P et al. Cyclosprin A initially as the only immunesuppressant 34 recipients of cadaveric organs: 32 kidneys, 2 pancreases and 2 livers. Lancet 2:1033-1036,1979.
4. Frecnch-Constant C, Wolman J, Geraaint JD. Cyclosperine in Behcet's disease. Lancet 2:454, 1983.
5. Starzl TE, Weil R, Iwatsuki S, Klintmalm G, Schroter, GPJ, Koep LJ, Iwaki Y, Terasaki PI, Porter KA. The use of cyclosporin A and prednisone in cadaver kidney transplantation. Surg Gynecol & Obstet 151:17-26, 1980.
6. Nussenblatt RB, Palestine AG, Chan C, Michizuki M, and Yancy K. Effectiveness of Cyclosperin therepy for Bechet's disease. Arthritis and Rheumatism 28: 671-679. 1985.
7. Nussenblatt RB, Palestine AG, Rook AH,Scher I, Wacker WB, Gery I. Treatment of intraocular inflammatory disease with Cyclospoeine A. Lacent 2:235-238. 1983.
8. Palestine AG, Nussenblatt RB, Chan C. Side effects of systemic cyclosporine in patients not undergoing transplantation. American J Medicine. 77:652-656, 1984.
9. Nuller W, Herrmann B. Cyclosporin A for psoriasis. New england J medicine. 301:555,1979.
10. Velthius PJ, Jessrun RFM. Improvement of Ichthyosis by cyclosporine. Lacent 1:335, 1985
11. Paroid A, Rebora A. Tpoical Cyclosporine in Alopecia Areata. Archiv of Dermatology 123:165-166,1987.
12. Thivolet J. Barthelemy H, Rigot-Muller G,Bendelac A. Effects of Cyclosporine on Bullous pemphigoid and pemphigus. Lacent 11:770-773, 1985.
13. Puttick L, Pollock A, Faifburn E. Treatment of Sezaryu syndrome with Cyclosporine A. J roval Socisty of Medicine 76:1063-1065,1982.
14. Totterman TH, Sheynius A, Killander A, et al. Treatment of therapy-resistant Sezary syndrome with Cyclosporine A: Suppression of Pruritius, Leukaemic T cell Activation Markers And Tumour Mass. Scandinavian J Haemayology. 34:196-203,1985.
15. Bendtzen K, Tvede N, Adersen V, et al. Cyclosporine for polymyositis. Lancet 1:792-793,1984.
16. Zebel P, Leimenstoll G, Gross WL. Cyclosporine for acute dermatomyositis. Lancet1:343 ,1984.
17. Feutren G, Querin S, Tron F, et al. The Effects of cyclosporine In Patients with Systemic Lupus. Transplantation proceedings. 18:643-644, 1986.
18. Allison MC, Pounder RE. Cyclosporinein for Crohn's disease. Lacent 1:902-903, 1984.
19. Gupta S, Keshavarizian A, Hodgson HJF. Cyclosporine in uncerative colitis. Lacent 2: 1277-1278,1984.
20. Routhier G, Epstein O, Janossy G, et al. Cyclosporine A on suppressor and inducer T lymphocytes in primary biliary cirrhosis.
21. Mcgregor Am, Beck L, Hall R. Cyclosporine A in management of Graves' disease. J Royal Society of medicine.
22. Tindall RSA, Rolling JA, Philips JT, et al. Preliminary results of A doubleblind randomized Placebo-controlled Trial of Cyclosporine in myasthenia gravis. New England J Medicine. 316: 719-724,1987.
23. Rebuck AS, Stoller CR, Braude AC, et al. Cyclosporine for pulmonary sarcoidosis. Lancet 1:1174,1984.
24. Stryckmans PA, Dumont JP, Velu TH, Debusscher L. Cyclosporine in refractory severy aplastic anemia. New England J Medicine. 310:655-656,1984.
25. Bueding E, Hawakins J, Cha YN. Antischistosomal effects of Cyclosporine A. Agents and Actions 11:380-383,1981.
26. Thommen-Scott K, Antimalarial activity of Cyclosporine A. Agents and Actions 11:770-773,1981.
27. Hamilton DV, Evans DB,Thirus S. Toxicity of Cyclosporine A in organ graftingl in :Cyclosporine A, ed D.J.G.White. P: 393-411.
28. Graffenring B Von, Krupp P. Side effects of Cyclosporine in Renal transplant recipeints and in patients with autoimmune disease. Transplantation Proceeding. 18:876-833, 1986.
29. Laupacis A, Keown PA, Ulan RA, Mckenzie N, et al. Cyclosporine A: A powerful immunosuppressant. Canadian Medical Association Journal. 126:1041-1046,1982.
30. Penn I. Kaposi's Sarcoma in immunosuppressed patients. J Clinical & Laboratory Immunology. 12: 1-10, 1983.
31. Laupacis A, Keown PA, Ulan RA, Sinclair NR, Stiller CR. Hyper-ilirubinemia and cyclosporine A level. Lance 2:1426-7,1981.
32. Ota B, Bradley M. Side effects of cyclosporine in 100 renal allograft recipients. Transplant Proc 15:3150-6, 1983.
33. Starzl TE, Weil R, Iwatsuki S, Klintmalm G, Schorter, GPJ, Koep LJ, Iwaki Y, Terasaki PI, Porter KA. The use of cyclosporin A and prednisone in cadaver kidney transplantation. Surg Gynecol & Obstet 151:17-26, 1980.
34. Thiru S, Calne RY, Nagington J. Lymphoma in renal allograft patients treated with cyclosporine A as one of the immunosuppressive agents. Transplant Proc 13:359-64,1981.
35. Daley TD, Wysocki GP, Mamandras AH. Orthodontic therapy in the patient treated with cyclosporine. Am J Orthod Dentofac Orthop 100:537-541,1991.
36. Rostock MH, Fry HR and Turner JE. Severe gingival overgrowth associated with cyclosporine therapy. J Perodontol 57:294-299, 1986.
37. Epstein S, Schlosberg M, Fallon M, et al. 1,2-dihydroxy-vitamin D3 modifies cyclosporin-induced bone loss. Calcif Tissue Int 47:152-157,1990.
38. Movsowitz C, Epstein S, Fallon M, Ismail F, Thomas S. Cyclosporin A in vivo produces severe osteopenia in the rats: effect of dose and duration of administration. Endocrinol 123:2571-2577, 1988.
39. Schlosberg M, Movswitz C, Epstein S, Ismail F, Fallon M, Thomas S. The effect of cyclosporin A administration and its with drawl on bone mineral metabolism in the rats. Endocrinol 124:2179-2184,1989.
40. Stewart PJ, Stern PH. Cyclosporines: correlation of immunosuppressive activity and inhibition of bone resorption. Calcif Tissue Int 45:222-226,1989.
41. Sagawa K, Fugibayashi S, Okano K, et al. Different inhibitory actions of immuno-modulating agents and immunosuppressive agents on bone resorption of mouses calvaria. Int J Immunopharmac 11:953-959,1989.
42. McCauley LK, Rosol TJ, Capen CC. Effects of cyclosporin A on rat osteoblasts (ROS 17/2.8 cells) in vitro. Calcif Tissue Int 51:291-297,1992.
43. Chowdhury MH, Shen V, Dempster DW. Effects of cyclosporine A chicken osteoclasts in votro. Calcif Tissue Int 49:275-279,1991.
44. Klaushofer K, Hoffman O, Stewart PJ, Czerwenka E, Koller K, Peterlik nM, Stern PH. Cyclosporine A imhitits bone resorption in culturesd neonatal mouse calvaria. J Pharmacol Exp Ther 243:584-590,1987.
45. Wilmink JM, Bras J, Surachno S, vHeyst JLAM, vdHorst JM. Bone repair in cyclosporin-treated renal transplant patient. Transplant Proc 21:1492-1494,1989.
46. Li XQ, Stevenson S, Klein L, Davy DT, Shaffer JW, Goldberg VM. Differential patterns of incorporation and remodeling among various types of bone grafts. Acta Anat 140:236-244,1991.
47. Reznik, VM, Berger, JS, Jones, KL, Mendoza, SA. Cyclosporine induces abnormal facial bone growth in children: a preliminary study. Pediatr Nephrol 3,296-299,1989.
48. Fu E, Nieh S, Chang HL, Wang SL. Cyclosporin-A induced gingival overgrowth in rats: Macroscopic and microscopic observation. Int J Periodontics Restorative Dent 16:278-291, 1996.
49. Ruffel B, Donatsch P, Madorin M, et al. Toxicological evaluation of Cyclosporine A. Arch Toxicol 53:107-141, 1983.
50. Wysocki GP, Gretzinger HA, Laupacis A, Ulan RA, Stiller CR. Fibrous hyperplasia of the gingiva: A side effect of cyclosporine Atherapy. Oral Surg Oral Med 55:274-278,1983.
51. Seymour RA, Smith DG. The effect of a plaque control programme on the incidence and severity of cyclosporin-induced gingival changes. J Clin Periodontol 18:107-116, 1991.
52. McGaw T, Lam S.Coates J. Cyclosporine-induced gingival overgrowth: correlation with dental plaque scores, gingival scores, and cyclosporin levels in serum and saliva. Oral Surg Oral Med Oral Pathol 64:293-297,1987.
53. Perun HE, Perun LMH, Huttunen KRH, et al. Gingival overgrowth among renal transplant recipients related to immunosuppressive medication and possible local background factors. J Periodontol 63:548-553,1992.
54. Tyldesley WR, Rotter E. Gingival hyperplasia induced by cyclosporin A. Br Dent J 157:305-309,1984.
55. Adams D, Daavies G. Gingival hyperplasia associated with cyclosporin. Br Dent J 157:89-90,1984.
56. Bartold PM. Cyclosporine and gingival overgrowth. J oral Pathol.16: 463-468.
57. Deliliers GL, Samtoro F, Polli N, Bruno E, et al. Light and electron microscopic study of cyclosporine A-induced gingival hyplasia. J Periodontol 57:771-775. 1986.
58. Pisanty S, Shoshan S, Chajek T et al. 59:599-603,1988.
59. Angelopolous A. Diphenylhydantion gingival hyperplasia: A clinicopathological review, I. Incidence, clinical features and histopathology. J Can Dent Assoc 2:103-109,1975.
60. Morisaki I, Kitamura K, Kato K, Marukawa Y, Mihara J. Age dependency of Cyclosporine A-induced gingival overgrowth in rats. Pediatr Dent 15:414-417,1993.
61. Nishikawa S, Nagata T, Morisaki I, et al. Pathogenesis of drug-induced gingival overgrowth. A review of studies in the rat model. J Periodontol 67:463-471,1996.
62. Earl F, Shin N, Hou-Li C and Shiao-Long W. Dose-dependent gingival overgrowth induced by Cyclosporine in rats. J Periodontal 66:594-598,1995.
63. Earl F, Shin N, Ulf M.E.Wikesjo, et al. Gingival overgrowth and dental alveolar alterations: Possible mechanisms of Cyclosporin-induced tooth migration. An experimental study in the rat. J Periodontal 68:1231-1236,1997.
64. Hwai-Nan Chang, DDS, PhD, et al. Angiogenesis and osteogenesis in an orthopedically expanded suture. Am J Orthod Dentofac Orthop 111:382-390,1997
65. Hwai-Nan Chang, Lawrence P. Garetto, Thomas R. Katona, et al. Angiogenesis and cell migration in an orthopaedically expanded maxillary structure in the rat. Archs oral Biol 41:985-994,1996